Contrasting Heart Test Laboratories (NASDAQ:HSCS) and Bone Biologics (NASDAQ:BBLG)

Heart Test Laboratories (NASDAQ:HSCS) and Bone Biologics (NASDAQ:BBLG) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation.

Risk & Volatility

Heart Test Laboratories has a beta of 3.16, suggesting that its stock price is 216% more volatile than the S&P 500. Comparatively, Bone Biologics has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500.

Profitability

This table compares Heart Test Laboratories and Bone Biologics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Heart Test Laboratories	N/A	-144.12%	-94.48%
Bone Biologics	N/A	-154.18%	-130.06%

Valuation & Earnings

This table compares Heart Test Laboratories and Bone Biologics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heart Test Laboratories	$18,600.00	122.03	-$6.61 million	($48.00)	-0.07
Bone Biologics	N/A	N/A	-$8.95 million	N/A	N/A

Heart Test Laboratories has higher revenue and earnings than Bone Biologics.

Analyst Ratings

This is a breakdown of current ratings for Heart Test Laboratories and Bone Biologics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heart Test Laboratories	0	0	1	0	3.00
Bone Biologics	0	0	0	0	N/A

Heart Test Laboratories currently has a consensus price target of $15.00, suggesting a potential upside of 333.53%. Given Heart Test Laboratories’ higher possible upside, research analysts clearly believe Heart Test Laboratories is more favorable than Bone Biologics.

Institutional & Insider Ownership

17.2% of Heart Test Laboratories shares are held by institutional investors. Comparatively, 34.3% of Bone Biologics shares are held by institutional investors. 2.7% of Heart Test Laboratories shares are held by insiders. Comparatively, 13.0% of Bone Biologics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Heart Test Laboratories beats Bone Biologics on 7 of the 9 factors compared between the two stocks.

About Heart Test Laboratories

Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.